{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T08:42:16Z","timestamp":1769330536432,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our objective was to assess the efficacy of golimumab (GLM) in patients with poor prognostic factors (PPFs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a post hoc analysis of GO-FORTH Phase 2\/3 study. Cluster analysis was used to determine a patient population with high-risk patterns based on seven PPFs suggested by the European Alliance of Associations for Rheumatology recommendations and limited physical function. Radiographic progression, disease activity, and physical function and associated factors were evaluated over 52\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 261 rheumatoid arthritis patients were classified into three clusters characterised by high disease activity, high C-reactive protein levels, and limited physical function at baseline. GLM showed suppression of progressive modified total sharp score and decreases in Disease Activity Score 28-joint counts with erythrocyte sedimentation rate and Health Assessment Questionnaire \u2013 Disease Index, in all the clusters. In Cluster C that showed almost all the PPF characteristics, a higher rate of change in modified total sharp score \u22640 was observed in GLM 100\u2009mg group than in GLM 50\u2009mg group (63.9% versus 46.5%). C-reactive protein concentration and physical limitation were associated with radiographic progression of Cluster C in GLM treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GLM was effective in rheumatoid arthritis patients in a subpopulation at high risk of PPF in GO-FORTH study. A dose of 100\u2009mg may be more beneficial in preventing radiographic progression in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae037","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T21:11:54Z","timestamp":1716412314000},"page":"1125-1134","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of golimumab in rheumatoid arthritis patients at high risk of a poor prognosis: <i>Post hoc<\/i> analysis of GO-FORTH study using cluster analysis"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1830-4382","authenticated-orcid":false,"given":"Teita","family":"Asano","sequence":"first","affiliation":[{"name":"Immunology Infectious Disease Department, Medical Affairs Division, Janssen Pharmaceutical K.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Ishii","sequence":"additional","affiliation":[{"name":"Immunology Infectious Disease Department, Medical Affairs Division, Janssen Pharmaceutical K.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Evidence Generation Department, Medical Affairs Division, Janssen Pharmaceutical K.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Masuda","sequence":"additional","affiliation":[{"name":"Immunology Infectious Disease Department, Medical Affairs Division, Janssen Pharmaceutical K.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"2024110410412361600_R1","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1266-4","article-title":"Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies","volume":"19","author":"Albrecht","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2024110410412361600_R2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024110410412361600_R3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2024110410412361600_R4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrrheum.2009.157","article-title":"Prognostic factors in rheumatoid arthritis in the era of biologic agents","volume":"5","author":"Skapenko","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"2024110410412361600_R5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.semarthrit.2018.09.003","article-title":"Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts","volume":"48","author":"Baganz","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024110410412361600_R6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40744-019-00174-7","article-title":"Efficacy of abatacept and adalimumab in patients with early rheumatoid arthritis with multiple poor prognostic factors: post hoc analysis of a randomized controlled clinical trial (AMPLE)","volume":"6","author":"Fleischmann","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2024110410412361600_R7","first-page":"53","article-title":"Efficacy and safety of filgotinib in patients with high risk of poor prognosis who showed inadequate response to mtx: a post hoc analysis of the FINCH 1 study","volume":"10","author":"Combe","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2024110410412361600_R8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001621","article-title":"Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3","volume":"7","author":"Aletaha","year":"2021","journal-title":"RMD Open"},{"key":"2024110410412361600_R9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2024110410412361600_R10","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1093\/rheumatology\/keaa820","article-title":"The number of risk factors for persistent disease determines the clinical course of early arthritis","volume":"60","author":"Luurssen-Masurel","year":"2021","journal-title":"Rheumatology"},{"key":"2024110410412361600_R11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1106-y","article-title":"Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials","volume":"18","author":"Landewe","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024110410412361600_R12","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/ard.2009.121160","article-title":"A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the best study","volume":"69","author":"Visser","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024110410412361600_R13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrrheum.2013.215","article-title":"Risk estimation in rheumatoid arthritis: from bench to bedside","volume":"10","author":"van der Helm-van Mil","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2024110410412361600_R14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/acr.21870","article-title":"Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis","volume":"65","author":"Lillegraven","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2024110410412361600_R15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"2024110410412361600_R16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2011.200317","article-title":"Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study","volume":"71","author":"Tanaka","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024110410412361600_R17","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/annrheumdis-2012-201796","article-title":"Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2\/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks","volume":"72","author":"Takeuchi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024110410412361600_R18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/14397595.2015.1109762","article-title":"Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024110410412361600_R19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/14397595.2015.1086041","article-title":"Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: post hoc analysis of the GO-FORTH study","volume":"26","author":"Tanaka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024110410412361600_R20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/annrheumdis-2018-214918","article-title":"Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis","volume":"78","author":"Aletaha","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024110410412361600_R21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/03009742.2011.594964","article-title":"Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression","volume":"41","author":"Dirven","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2024110410412361600_R22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024110410412361600_R23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41590-019-0526-7","article-title":"Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1","volume":"20","author":"Hasegawa","year":"2019","journal-title":"Nat Immunol"},{"key":"2024110410412361600_R24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1063-4584(03)00156-0","article-title":"Influence of pro-inflammatory (IL-1 alpha, IL-6, TNF-alpha, IFN-gamma) and anti-inflammatory (IL-4) cytokines on chondrocyte function","volume":"11","author":"Schuerwegh","year":"2003","journal-title":"Osteoarthritis Cartilage"},{"key":"2024110410412361600_R25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.11487","article-title":"Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction","volume":"50","author":"Zwerina","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024110410412361600_R26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/ard.2011.153023","article-title":"Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis","volume":"70","author":"Takeuchi","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024110410412361600_R27","first-page":"55","article-title":"Radiological progression in established rheumatoid arthritis","volume":"69","author":"Scott","year":"2004","journal-title":"J Rheumatol Suppl"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae037\/57982469\/roae037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/6\/1125\/60412177\/roae037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/6\/1125\/60412177\/roae037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T10:41:36Z","timestamp":1730716896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/6\/1125\/7680335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,23]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae037","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,23]]}}}